At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Apr 27, 2026 at 09:01 ET
Alpha Tau Medical announced abstract acceptance of pooled clinical data from 58 pancreatic cancer patients at the 2026 ASCO Annual Meeting, a prestigious oncology conference. The company also reported Q4 2025 earnings with an EPS of $-0.08, beating consensus by 35.3%, though revenue was minimal at $66K. The ASCO recognition signals growing scientific validation for its Alpha DaRT therapy.
- Q4 2025 EPS: $-0.08 (consensus: $-0.12), representing a 35.3% beat
- Revenue: $66K (in line with estimates)
- Abstract on Alpha DaRT for pancreatic cancer accepted at ASCO 2026 Annual Meeting
- Data pooled from 58 patients across three clinical studies in Canada and Israel
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access